Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tiziana Life Sciences Ltd TLSA
$0.79
-$0.03 (-3.44%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
80249904.00000000
-
week52high
1.39
-
week52low
0.50
-
Revenue
0
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-0.15000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 апр 2023 г. в 02:00
Описание компании
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| ThinkEquity | Buy | 13 июн 2022 г. | |
| Zacks Investment Research | Not Rated | 12 апр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 21 сент 2020 г. |
| ThinkEquity | Buy | 06 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Tiziana shares positive findings on intranasal foralumab in treating intracerebral hemorrhage
Proactive Investors
27 апр 2023 г. в 09:26
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported promising in-depth findings on the utility of its lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb), in the treatment of intracerebral hemorrhage (ICH), a subtype of stroke. The New York-based biopharmaceutical company said the data using a mouse model of collagenase-induced ICH was shared in a presentation at the Annual American Academy of Neurology conference.
Tiziana Life Sciences provides update on development pipeline
Proactive Investors
26 апр 2023 г. в 15:44
Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022. The biotechnology company's interim CEO Gabriele Cerrone said that, after it announced in late 2022 its near-term focus on advancing intranasal foralumab to address central nervous system-mediated inflammatory diseases, Tiziana has started this year with a stream of continuous, positive program-related developments.
Tiziana Life Sciences to develop Foralumab for type 1 diabetes
Proactive Investors
18 апр 2023 г. в 07:34
Tiziana Life Sciences Ltd (NASDAQ:TLSA) (Tiziana Life Sciences Ltd (NASDAQ:TLSA)) has announced the initiation of a program to develop intranasal Foralumab as a treatment or prevention method for type 1 diabetes. The move comes after the US Food & Drug Administration approved the humanized anti-CD3 monoclonal antibody, TZIELD (teplizumab-mzwv), a new injected drug for the condition.
Tiziana Life Sciences plans to investigate intranasal foralumab for the treatment of Long COVID
Proactive Investors
13 апр 2023 г. в 07:58
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced plans to investigate intranasal foralumab for the treatment of Long COVID, work which is supported by foralumab's well-established role in de-activating microglia cells, a key component in the pathogenesis of the disease. “We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA”, commented Dr Matthew W.
Tiziana Life Sciences says intranasal foralumab presented at ‘Preserving the Brain' scientific conference and exhibit in Shanghai
Proactive Investors
10 апр 2023 г. в 08:08
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that poster presentations on intranasal foralumab are being presented at the ‘Preserving the Brain' scientific conference and exhibit at the Fondazione Prada Rong Zhai in Shanghai, China. The company explained that ‘Preserving the Brain' is a scientific forum and exhibit on neurodegenerative diseases as part of the ‘Human Brains' neuroscience project.